Trials / Completed
CompletedNCT04965506
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 252 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI362 | IBI362 administered subcutaneously (SC) once a week. |
| OTHER | placebo | placebo administered subcutaneously (SC) once a week. |
| OTHER | Dulaglutide | Dulaglutide administered subcutaneously (SC) once a week. |
Timeline
- Start date
- 2021-09-06
- Primary completion
- 2022-04-28
- Completion
- 2022-06-11
- First posted
- 2021-07-16
- Last updated
- 2023-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04965506. Inclusion in this directory is not an endorsement.